COVID-19 vaccines available in 2023-2024 were still offering extra protection

Embargoed until: Publicly released: 2025-06-26 01:00

International

Photo by Mufid Majnun on Unsplash

People who received the new COVID-19 vaccines available in 2023-2024 - targeting the XBB.1.5 Omicron variant - saw increased protection from hospitalisation and critical illness above general immunity from previous vaccines and infections, according to international research. The team used data from almost 350,000 emergency department presentations and over 100,000 hospitalisations in the US to find COVID-19 patients and estimate the effectiveness of the vaccines in circulation at the time. They estimate that on top of the protection against COVID-19 most people have now from prior vaccination and getting the virus, the vaccines were 29% effective against emergency department presentations, 30% effective against hospitalisation and 48% effective against critical illness, with vaccine efficiency highest from one week to two months after vaccination.

Media release

From: JAMA

Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults

About The Study: In this case-control study of vaccine effectiveness, 2023-2024 COVID-19 vaccines were estimated to provide additional effectiveness against medically attended COVID-19, with the highest and most sustained estimates against critical illness. These results highlight the importance of receiving recommended COVID-19 vaccination for adults 18 years or older.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Centers for Disease Control and Prevention, USA

Funder: Dr Klein reported receiving grants from Pfizer, Moderna, Merck, GlaxoSmithKline, Seqirus, AstraZeneca, and Janssen outside the submitted work. Dr Ball reported receiving funding from University of Utah outside the submitted work. Dr DeSilva reported receiving grants from Minnesota Department of Health outside the submitted work. Dr Naleway reported receiving grants from the National Institutes of Health outside the submitted work. Dr Zerbo reported receiving grants from Pfizer and Moderna outside the submitted work. Dr McEvoy reported receiving grants from GlaxoSmithKline, Astra-Zeneca, National Heart, Lung, and Blood Institute, and US Department of Defense outside the submittedwork. No other disclosures were reported.

Media Contact/s

Contact details are only visible to registered journalists.